Tuesday 19th September 2017
2:00-3:00 pm (UK Time)
(Organised by the Toxicology Special Interest Group)
Presenter: David Lovell, St George’s Medical School, University of London
The bacterial reverse mutation assay (or the Ames test) has been in use in its present form for over 40 years. It is arguably the most successful in vitro test, used by hundreds of laboratories worldwide, on thousands of substances. The test aims to identify substances that can produce genetic damage and may lead to cancer in exposed individuals or to inherited mutation in offspring to cancer.
The design of the test is basically simple and numerous statistical tests have been proposed for the analysis of the data produced. Interpretation of the result aims at categorizing the chemical as either a genotoxin or a non-genotoxin. This provides an interesting example of the contrast between statistical significance and biological interpretation. Ames test results are also used in helping to develop in silico methods for predicting carcinogenicity.
This presentation will illustrate these issues and also discuss newer versions of the test and the continuing assessment of the role of the test in toxicology.
PSI Webinar: Wearable Technologies - Challenges and Opportunities
Wearable technologies and digital health data offer great opportunities for studying patients functionally in real life settings. Actigraphy, for example, can be used as part of clinical trials to collect continuous movement data, but the frequency of data collection results in dense datasets requiring extensive processing and signal detection. In this webinar, a panel of expert speakers will discuss how such aspects can be addressed to help realize the promise of these technologies.
Our annual PSI Medical Statistics Careers Event, will be held online using the Career Fair Plus app on Wednesday 3rd March 2021. The event will include a live online panel discussion and a virtual exhibition session.
Discover your extraordinary potential by working as a Covance AD, Biostatistics / Senior Principal Biostatistician. You will consult in the design of complex and innovative studies & clinical trial programs as well as Leading DMC/DSMB processes.
By joining our company, in this role you will apply your skills and experience in support of developing scientifically based arguments aiming to provide fair accessibility to our company’s drugs and vaccines making a real difference in patient’s lives.
Senior Principal / Principal Biostatistician (Oncology) – FSP
Join our team as a Covance FSP Senior Principal or Principal Biostatistician. You will be assigned to one Sponsor working on Phase I and II oncology studies. Previous Lead experience essential. Office or home-based anywhere in Europe or South Africa.
